Peak months of pandemic ’s first-wave in India: a cross-sectional assessment of knowledge, attitudes and practice towards COVID-19 among internet-savvy individuals
ConclusionsThe results obtained add significant value to the existing KAP literature on COVID-19 in India and may help policymakers achieve public compliance with preventive measures. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - February 10, 2022 Category: Drugs & Pharmacology Source Type: research
RETRACTED ARTICLE: The Role of Vitamin C in the Treatment of Sepsis
(Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - February 9, 2022 Category: Drugs & Pharmacology Source Type: research
The Role of Vitamin C in the Treatment of Sepsis
AbstractSevere viral or bacterial infections can lead to sepsis and multiorgan dysfunction, and these latter events can even cause death. Multiple lines of evidence in the literature associate vitamin C with antioxidant, anti-inflammatory, anticoagulant and immunomodulatory actions. All of these biological effects make vitamin C a potential treatment for the prevention and treatment of sepsis. In this article, we briefly summarize the data supporting the use of vitamin C as a treatment for sepsis and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 is responsible for the current ongoing ...
Source: Drugs and Therapy Perspectives - February 9, 2022 Category: Drugs & Pharmacology Source Type: research
Oritavancin (KIMYRSA ™) in acute bacterial skin and skin structure infections: a profile of its use in the USA
AbstractOritavancin, a long-acting lipoglycopeptide, is the first single-dose intravenous (IV) antibacterial therapy approved in the USA for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSIs) caused or suspected to be caused by susceptible isolates of designated gram-positive microorganisms. With its well-established antibacterial activity, efficacy and safety profiles, a new IV formulation of oritavancin (KIMYRSA ™) has been developed to offer a more convenient treatment option for patients with ABSSSIs. Relative to the originally approved IV formulation of oritavancin (ORB...
Source: Drugs and Therapy Perspectives - February 5, 2022 Category: Drugs & Pharmacology Source Type: research
Viloxazine for attention-deficit hyperactivity disorder: a new formulation for a new indication
This article summarizes the information regarding viloxazine based on previously published narrative reviews, preclinical stu dies, and blinded controlled clinical trials. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - January 27, 2022 Category: Drugs & Pharmacology Source Type: research
Trilaciclib for the reduction of chemotherapy-induced myelosuppression in the management of extensive-stage small cell lung cancer: a profile of its use
AbstractTrilaciclib (COSELA ™) is a transient inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4/6) that is approved in the USA to decrease the incidence of chemotherapy-induced myelosuppression (CIM) when administered before a platinum/etoposide-containing regimen or topotecan-containing regimen in adults being treated fo r extensive-stage small cell lung cancer (ES-SCLC). It is the first approved therapy to provide myeloprotection, and when administered before chemotherapy, it is a valuable option for decreasing the incidence of CIM. In three clinical randomized trials, trilaciclib administration prior to standard-o ...
Source: Drugs and Therapy Perspectives - January 25, 2022 Category: Drugs & Pharmacology Source Type: research
Adverse drug reactions from two COVID-19 vaccines reported in Saudi Arabia
ConclusionThere were significant differences regarding most of the reported ADRs and their onset among tozinameran and ChAdOx1 vaccines on both healthy people and high-risk individuals living in Saudi Arabia. Moreover, the study found that the frequencies of most listed ADRs were statistically different when seven batches of tozinameran vaccine were compared. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - January 22, 2022 Category: Drugs & Pharmacology Source Type: research
A systematic review of the prevalence, determinants, and impact of potentially inappropriate prescribing in middle-aged adults
ConclusionPIP is common in MAA. There was moderate certainty for our findings for the prevalence of PIP and its association with female sex and polypharmacy. Certainty for other findings was either low or very low. No data were available to assess some of our pre-specified outcomes. Further studies are needed to examine whether PIP is associated with negative outcomes in MAA. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - January 21, 2022 Category: Drugs & Pharmacology Source Type: research
Voclosporin in lupus nephritis: a profile of its use
AbstractVoclosporin (Lupkynis ™), a novel calcineurin inhibitor, is approved in the USA as an add-on to background immunosuppressive therapy in adults with active lupus nephritis. Voclosporin, in combination with mycophenolate mofetil and low-dose corticosteroids, achieved higher complete renal response rates in adults with ac tive lupus nephritis than mycophenolate mofetil and low-dose corticosteroids alone. Voclosporin treatment led to early and sustained reductions in proteinuria. Voclosporin was generally well tolerated, with no unexpected adverse events. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - January 17, 2022 Category: Drugs & Pharmacology Source Type: research
Frailty and rate of fractures in patients initiating antihypertensive medications: a cohort study in primary care
ConclusionsFrailty is common among older patients initiating first-line antihypertensive treatment, and was associated with an increased fracture rate. Awareness of this is important to encourage clinicians to consider risk of falls and fractures when treating hypertension. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - January 15, 2022 Category: Drugs & Pharmacology Source Type: research
First reports of adverse drug reactions
(Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - January 3, 2022 Category: Drugs & Pharmacology Source Type: research
The pharmacist survival guide: COVID-19 workflow modifications and crisis management in the surgical setting
(Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - December 9, 2021 Category: Drugs & Pharmacology Source Type: research
Eczematous drug eruptions mostly manageable with emollients and corticosteroids
AbstractEczematous drug eruptions (EDEs) constitute up to 10% of cutaneous drug reactions, with biologics and some newer cancer treatments and antivirals regularly implicated. EDEs are generally mild, although bacterial superinfection is a risk. Drug withdrawal and rechallenge, where practical, is the gold standard diagnostic test. Dry skin, cutaneous immunomodulation and sometimes type IV hypersensitivity reactions underlie EDEs and treatments reflect this, with most patients responding to emollients and corticosteroids. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - December 6, 2021 Category: Drugs & Pharmacology Source Type: research
Glutamatergic modulators are poorly understood, but promising therapies in depressive disorders
AbstractTreatment-resistant depression (TRD) affects many people with major depressive disorder or bipolar disorder. Glutamate is the key excitatory neurotransmitter in the CNS, and the confirmed rapid-acting antidepressant (RAAD) efficacy of the glutamatergic agent ketamine has fuelled extensive research into other glutamatergic agents. While mixed results have been reported in clinical trials, several glutamate receptor antagonists, including glycine site modulators, show promise as RAADs for severe TRD. The place of glutamatergic agents in the hierarchy of treatment for TRD is yet to be determined as more robust long-te...
Source: Drugs and Therapy Perspectives - November 27, 2021 Category: Drugs & Pharmacology Source Type: research
Antibiotic prescribing patterns for acute respiratory infections in a free clinic network: a pooled cross-sectional study
AbstractIn the United States, overprescribing of antibiotics for viral respiratory infections and antimicrobial resistance continue to be public health concerns. To date, no literature has focused on antibiotic prescribing patterns from free clinics. To address this gap, we used patient-level data from a student-run free clinic network of four primary care clinics to assess factors associated with inappropriate antibiotic prescribing for viral respiratory infections. Treatment plans were deemed inappropriate if any type of antibiotic was prescribed. We used unpairedt tests and chi-square tests to assess for differences in ...
Source: Drugs and Therapy Perspectives - November 24, 2021 Category: Drugs & Pharmacology Source Type: research
